Clinical Trial

A Study of KM602 in Patients With Advanced Solid Tumors

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.
Trial Details
NCT Number NCT05766527
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 38 participants
Start Date 2023-04
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-03-13